Form 8-K - Current report:
SEC Accession No. 0001213900-24-077706
Filing Date
2024-09-11
Accepted
2024-09-11 16:01:33
Documents
16
Period of Report
2024-09-05
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0214273-8k_raphael.htm   iXBRL 8-K 32357
2 LETTER FROM WEINSTEIN INTERNATIONAL CPA, ADDRESSED TO THE SECURITIES AND EXCHANG ea021427301ex16-1_raphael.htm EX-16.1 7272
3 GRAPHIC ex16-1_001.jpg GRAPHIC 10242
4 GRAPHIC ex16-1_002.jpg GRAPHIC 24799
  Complete submission text file 0001213900-24-077706.txt   259539

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE raph-20240905.xsd EX-101.SCH 3054
6 XBRL LABEL FILE raph-20240905_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE raph-20240905_pre.xml EX-101.PRE 22385
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0214273-8k_raphael_htm.xml XML 3354
Mailing Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108
Business Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108 702-442-1166
Raphael Pharmaceutical Inc. (Filer) CIK: 0001415397 (see all company filings)

EIN.: 260204284 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-53002 | Film No.: 241292581
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)